ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Eli Lilly to aquire pain biotech CoLucid for $960 million
europeanpharmaceuticalreview
January 20, 2017Eli Lilly and Company will acquire CoLucid Pharmaceuticals for $46.50 per share or approximately $960 million. This all-cash transaction will enhance Lilly’s existing portfolio in pain management for migraine, while adding a potential near-term launch to
Pharma Sources Insight January 2025
